IgA Nephropathy (Berger’s Disease): The Most Common Primary Glomerular Disease

Imagine microscopic immune complexes depositing in your kidneys causing progressive inflammation and scarring. Your kidneys gradually lose function. Blood appears in your urine. Protein leaks into urine. Kidney failure develops. You face dialysis or transplantation. This is IgA nephropathy—the most common primary glomerulonephritis worldwide, where immune complexes containing immunoglobulin A deposit in the kidney’s glomeruli causing progressive kidney damage. IgA nephropathy, also called Berger’s disease, is an autoimmune kidney disease characterized by deposition of immunoglobulin A (IgA) immune complexes in the glomeruli—the kidney’s filtering units. The immune complex deposition triggers inflammation. Inflammatory cells infiltrate the glomeruli. The glomeruli become damaged. Glomerular function decreases. Protein and blood leak into urine. Progressive glomerular scarring develops. Eventually, kidney failure develops if untreated. IgA nephropathy affects approximately 1 to 2 per million people per year. The disease is the most common primary glomerulonephritis in developed countries. It is even more common in East Asia. Males are affected twice as frequently as females. The disease typically develops in children and young adults, though it can appear at any age. What makes IgA nephropathy particularly important is the variable disease course. Some patients remain asymptomatic for years with stable kidney function. Others progress rapidly to kidney failure within months. The variable progression makes predicting individual outcomes challenging. Early detection and treatment might slow progression. However, no cure exists for IgA nephropathy. Modern treatments including immunosuppressive therapy and blood pressure control have improved outcomes. With appropriate management, many patients maintain adequate kidney function. However, approximately 40 percent progress to kidney failure requiring dialysis or transplantation. In this comprehensive article, we will explore what IgA nephropathy is, understand how immune complex deposition damages kidneys, recognize early symptoms and diagnosis, learn about disease progression and complications, explore available treatments, and discover management strategies for slowing kidney disease progression and maintaining renal function.

Understanding Normal Kidney Structure and Function

Before we explore IgA nephropathy, we need to understand normal kidney structure and filtering function. The kidneys are bean-shaped organs located on either side of the spine in the retroperitoneum. Each kidney weighs approximately 150 grams. The kidneys receive approximately 20 percent of cardiac output—about 1 to 1.5 liters of blood per minute. The kidneys filter blood removing waste products while retaining essential substances. The nephron is the basic functional unit of the kidney. Each kidney contains approximately 1 million nephrons. Each nephron consists of a glomerulus (filtering unit) and a renal tubule (reabsorption unit). The glomerulus is a network of specialized capillaries. The glomerulus performs ultrafiltration—separating waste and excess water from blood. The glomerular filtration barrier consists of three layers: the endothelium (inner lining of capillaries), the basement membrane (protein scaffold), and the podocytes (specialized cells with foot processes). The filtration barrier is selective. Water and small solutes pass through into the Bowman’s capsule. Large molecules like proteins and blood cells are retained in blood. Approximately 180 liters of fluid is filtered daily. However, 99 percent is reabsorbed in the renal tubules. Only 1 to 2 liters becomes urine. Normal urine should contain no protein and no red blood cells. Protein in urine (proteinuria) indicates glomerular damage. Blood in urine (hematuria) indicates glomerular bleeding. The glomeruli are protected from excessive immune attack by several mechanisms. Regulatory proteins prevent complement activation. T regulatory cells suppress immune responses. Immune tolerance prevents autoimmunity. In IgA nephropathy, these protective mechanisms fail. IgA immune complexes deposit in the glomeruli. The complexes activate complement. Inflammatory cells infiltrate. The glomeruli are damaged. Understanding normal kidney function helps explain how IgA deposition disrupts filtering and causes disease.

What is IgA Nephropathy?

IgA nephropathy is a primary glomerulonephritis characterized by predominant IgA immune complex deposition in the glomeruli. The disease is named after the immunoglobulin A that deposits in the kidney. IgA is an antibody produced by B lymphocytes. Normally, IgA in the blood is maintained at controlled levels. In IgA nephropathy, excessive IgA is produced. Additionally, the IgA produced has abnormal structure. The IgA becomes glycosylated abnormally—sugar molecules are attached incorrectly. The abnormal glycosylation makes the IgA more likely to form immune complexes. The IgA immune complexes circulate in blood. The complexes deposit in kidney glomeruli. The IgA complexes activate the complement system. Complement cascade reactions produce inflammatory mediators. Inflammatory cells including macrophages and neutrophils infiltrate glomeruli. These cells produce additional inflammatory chemicals. The inflammatory environment damages glomeruli. Endothelial cells are damaged. The basement membrane is damaged. Podocytes are damaged. Glomerular scarring develops from the inflammatory damage. Progressive scarring leads to glomerular sclerosis—permanent hardening of glomeruli. The scarred glomeruli cannot filter. Kidney function progressively declines. What causes excessive IgA production in IgA nephropathy is incompletely understood. Genetic factors are important—IgA nephropathy runs in families. Specific genetic markers increase susceptibility. However, genetics alone does not cause disease. Environmental triggers are also necessary. Infections have been suspected as triggers. Upper respiratory infections and gastrointestinal infections might trigger IgA production. The infections might activate B cells producing IgA antibodies. Additionally, the infections might alter IgA glycosylation. Mucosal immunity appears important. IgA is produced by lymphocytes in the mucosa of respiratory and digestive systems. Excessive IgA production in mucosal tissue contributes to systemic IgA elevation. Intestinal dysbiosis—abnormal bacterial composition—might contribute. Dysbiosis might promote excessive IgA production. What causes abnormal IgA glycosylation is unknown. Defective glycosylation might result from genetic factors. Acquired glycosylation defects might result from infections or other triggers. The abnormal glycosylation makes IgA more immunogenic—more likely to trigger immune response. The abnormal IgA forms complexes with anti-IgA antibodies. These immune complexes deposit in glomeruli. Complement activation and inflammation follow. IgA nephropathy is classified by kidney biopsy findings. The Oxford Classification grades IgA nephropathy based on extent of sclerosis, endocapillary proliferation, segmental sclerosis, tubular atrophy, and interstitial fibrosis. The grade helps predict prognosis. Higher grades correlate with worse long-term outcomes.

Recognizing Early Symptoms: The Variable Presentation

IgA nephropathy symptoms are variable and often nonspecific. Many patients are asymptomatic, discovered only by blood or urine testing. Recognizing symptoms when they occur prompts medical evaluation. Hematuria (blood in urine) is the most common finding. Gross hematuria—visible blood in urine—develops acutely. Urine becomes tea-colored or dark red. Gross hematuria is often the symptom prompting evaluation. Gross hematuria episodes are sometimes triggered by upper respiratory infections. The patient might have cold symptoms followed days later by hematuria. Microscopic hematuria—red blood cells visible only under microscope—is found on routine urinalysis. Patients usually have no symptoms with microscopic hematuria. Proteinuria (protein in urine) develops. Small amounts of protein normally leak into urine. Proteinuria—elevated urinary protein—indicates glomerular damage. Proteinuria might be asymptomatic. Alternatively, foaming urine might be noticed from protein concentration. The foaming is particularly noticeable if urine is concentrated. Hypertension develops in some patients. Blood pressure elevation reflects kidney damage. Some patients are first diagnosed with high blood pressure before kidney disease recognition. Hypertension accelerates kidney disease progression. Abdominal or flank pain sometimes develops. The pain is sometimes referred to as kidney pain. However, kidneys do not have pain-sensing nerves. The pain likely results from stretching of renal capsule from swelling. Edema (swelling) develops in some patients. Facial puffiness develops from fluid retention. Peripheral edema affects legs. Ascites (abdominal fluid) develops if significant protein loss occurs. Edema indicates heavy proteinuria and declining kidney function. Fatigue develops. Anemia from chronic kidney disease causes tiredness. Uremia—accumulation of toxic waste products—causes lethargy. Reduced appetite develops. Appetite loss results from uremia. Nausea develops from uremia. Uremic symptoms indicate declining kidney function. Many early IgA nephropathy patients are completely asymptomatic. The disease is discovered on routine blood pressure check, during screening for other conditions, or on routine urinalysis. Asymptomatic patients with stable kidney function have better long-term prognosis than symptomatic patients. Early detection before symptoms develop allows earlier treatment potentially slowing progression.

Understanding Progressive Kidney Damage: From Inflammation to Fibrosis

Understanding how IgA deposition causes progressive kidney damage helps explain disease progression and why early treatment is important. IgA immune complex deposition initiates inflammation. Circulating IgA immune complexes deposit in glomeruli. The complexes are small enough to pass through glomerular basement membrane. The complexes deposit particularly at the mesangium—the central area of glomeruli. The mesangial cells engulf the complexes. Complement is activated by the deposited complexes. Inflammatory mediators are generated. Inflammatory cells infiltrate glomeruli. Endothelial cells are damaged. The glomerular filtration barrier becomes leaky. Protein leaks into urine. Blood cells leak into urine. Hematuria and proteinuria develop. Mesangial proliferation occurs. Mesangial cells multiply in response to inflammation. The proliferating cells fill the glomerulus. The mesangium becomes enlarged. This proliferation reduces glomerular filtration surface. Glomerular filtration decreases. Crescents develop in severe disease. Cellular crescents—proliferating cells filling Bowman’s capsule—develop. Crescent formation indicates severe glomerular damage. Crescents predict worse prognosis. Glomerular scarring develops. Fibroblasts produce collagen. Collagen accumulates replacing damaged glomerular tissue. Sclerosis—hardening and scarring—develops. Sclerotic glomeruli cannot filter. Glomerular sclerosis is irreversible. Progressive glomerulosclerosis occurs. Over years, more glomeruli become sclerotic. The number of functioning glomeruli decreases. Kidney function progressively declines. Interstitial fibrosis develops. The kidney tissue between nephrons becomes fibrosed. Tubular atrophy occurs. Kidney tubules become damaged and scarred. The combination of glomerulosclerosis, interstitial fibrosis, and tubular atrophy leads to end-stage kidney disease. Kidney function eventually becomes insufficient to maintain life. Dialysis or transplantation becomes necessary. The rate of progression varies dramatically. Some patients maintain stable kidney function for decades. Others progress rapidly to kidney failure within months. Factors predicting rapid progression include: high proteinuria at diagnosis, hypertension, severe histologic damage on biopsy, and male gender. Early identification of high-risk patients allows more aggressive treatment attempting to slow progression.

Diagnosis: Recognizing IgA Nephropathy

Diagnosing IgA nephropathy requires clinical suspicion, appropriate testing, and kidney biopsy. Clinical history is crucial. Doctors ask about hematuria history—particularly episodes triggered by infections. They ask about family history of kidney disease. They assess for systemic symptoms. Physical examination documents findings. Blood pressure is assessed—hypertension suggests kidney disease. Physical examination assesses for edema. Abdominal examination assesses kidney tenderness. Urine tests are performed. Urinalysis detects hematuria and proteinuria. Red blood cells and protein in urine indicate glomerular disease. 24-hour urine collection quantifies proteinuria. Proteinuria amount helps assess disease severity. Heavy proteinuria (>3 grams daily) indicates worse disease. Blood tests assess kidney function. Creatinine level indicates glomerular filtration rate. Elevated creatinine indicates reduced kidney function. Blood urea nitrogen (BUN) increases with kidney disease. BUN-to-creatinine ratio helps assess kidney function. Electrolytes are assessed. Potassium elevation develops with kidney disease. Sodium abnormalities develop. Calcium often decreases. Phosphorus increases. Albumin decreases with heavy proteinuria. Complement levels are assessed. C3 and C4 complements are usually normal in IgA nephropathy. Low complement levels suggest other glomerulonephritis types (lupus nephritis or post-infectious GN). Serologic tests are performed. ANA is negative in IgA nephropathy (distinguishing from lupus). ANCA is negative (distinguishing from ANCA-associated vasculitis). Kidney biopsy is definitive. A small kidney sample is obtained using ultrasound-guided needle biopsy. The tissue is examined by light microscopy, immunofluorescence, and electron microscopy. Light microscopy shows glomerular proliferation, crescent formation, sclerosis. Immunofluorescence shows IgA deposition in glomeruli. This is pathognomonic—diagnostic—for IgA nephropathy. Electron microscopy shows electron-dense deposits in mesangium. The combination of findings confirms diagnosis. Biopsy allows disease grading predicting prognosis. Early kidney biopsy helps determine treatment decisions. Ultrasound examines kidney size and echotexture. Kidney size decrease indicates chronic disease. Imaging screens for other abnormalities. Renal artery stenosis assessment prevents missing important diagnoses. The diagnosis of IgA nephropathy is confirmed by kidney biopsy showing predominant IgA deposition in glomeruli. Early diagnosis allows early treatment potentially slowing progression.

Treatment: Slowing Kidney Disease Progression

IgA nephropathy treatment aims to reduce proteinuria, slow glomerular damage, prevent progression to kidney failure, and manage associated hypertension. Blood pressure control is fundamental. Angiotensin-converting enzyme (ACE) inhibitors reduce proteinuria and slow disease progression. ACE inhibitors dilate the efferent arteriole of the glomerulus reducing intraglomerular pressure. The reduced pressure reduces proteinuria. Reduced proteinuria correlates with slowed progression. Typical ACE inhibitor doses range from 5 to 40 mg daily depending on the agent. Angiotensin receptor blockers (ARBs) are alternatives if ACE inhibitors cause cough or other side effects. ARBs have similar anti-proteinuric effects to ACE inhibitors. ACE inhibitors and ARBs should not be used together due to increased adverse effects. Blood pressure targets are typically less than 120/80 mmHg. Some patients require additional antihypertensive agents. Diuretics help manage fluid retention if present. Calcium channel blockers help blood pressure control. Beta-blockers help in specific situations. Diuretics, NSAIDs, and some other medications should be avoided as they might impair kidney function further. Immunosuppressive medications slow progression in some patients. Corticosteroids reduce inflammation. High-dose corticosteroids (e.g., methylprednisolone pulses followed by oral prednisone) are used in aggressive disease. Corticosteroids reduce mesangial proliferation and proteinuria. However, side effects limit long-term use. Mycophenolate mofetil (MMF) reduces inflammation. MMF is used in combination with corticosteroids for severe disease. MMF plus ACE inhibitors shows benefit in some studies. Azathioprine (AZA) suppresses immune response. AZA is sometimes used but evidence is limited. Cyclophosphamide is reserved for severe disease with crescents. The combination of ACE inhibitor plus cyclophosphamide plus corticosteroids is used for rapidly progressive disease. Fish oil (omega-3 fatty acids) might provide modest benefit. High-dose fish oil (2 to 4 grams daily) reduces mesangial inflammation. Conflicting studies exist regarding benefit. Fish oil is generally safe and might help. Anticoagulation is sometimes used. Antiplatelet therapy with aspirin might reduce progression. Evidence is limited. Anticoagulation is typically reserved for specific situations. Statins reduce cardiovascular risk. High cholesterol often develops in kidney disease. Statins reduce cardiovascular events common in kidney disease. Dietary management is important. Sodium restriction helps blood pressure control. Protein restriction (0.6 to 0.8 g/kg/day) might slow progression. Excess protein increases glomerular filtration pressure. Reducing protein reduces this pressure. However, severe protein restriction risks malnutrition. Balanced protein intake is usually recommended. Kidney transplantation is necessary if end-stage kidney disease develops. IgA nephropathy recurs in transplanted kidneys in approximately 50 percent of patients. However, recurrence is often clinically insignificant. Most transplant recipients have good long-term allograft function.

Living with IgA Nephropathy: Monitoring and Management

Living with IgA nephropathy requires regular monitoring, adherence to medications, dietary modification, and lifestyle adjustment. Regular nephrology appointments ensure disease monitoring. Kidney function tests assess creatinine and estimate GFR. Urine tests assess proteinuria and hematuria. Kidney function trending over time helps predict progression. More frequent monitoring is necessary if kidney function declines rapidly. Blood pressure monitoring is crucial. Home blood pressure monitoring helps assess control. Most patients should monitor blood pressure regularly. Target blood pressure less than 120/80 mmHg should be achieved. Taking ACE inhibitors or ARBs exactly as prescribed is essential. These medications must be taken regularly to maintain proteinuria reduction. Missing doses allows proteinuria to increase. Regular dosing maintains kidney protection. Medication adherence is crucial for slowing progression. Taking other antihypertensive medications as prescribed maintains blood pressure control. Additional medications including diuretics, calcium channel blockers, or beta-blockers must be taken consistently. Dietary management helps kidney disease control. Low-sodium diet (less than 2 grams daily) helps blood pressure control. Avoiding processed foods reduces sodium intake. Fresh foods are typically lower sodium. Moderate protein intake (0.6 to 0.8 g/kg/day) reduces glomerular workload. Meat, fish, eggs, and dairy should be portion-controlled. Adequate calories prevent malnutrition. Carbohydrates and healthy fats provide calories without excess protein. Adequate potassium and phosphorus restriction becomes necessary as kidney disease progresses. These minerals accumulate as kidney function declines. Avoiding potassium-rich foods (bananas, potatoes, tomatoes) helps maintain normal levels. Limiting phosphorus-rich foods helps maintain calcium-phosphorus balance. Hydration is important. Adequate fluid intake is necessary unless kidney function is severely declined. Dehydration worsens kidney function. Adequate hydration supports kidney perfusion. Exercise appropriate to kidney function helps overall health. Moderate exercise is usually safe. Excessive exertion might transiently increase proteinuria. Regular moderate activity is beneficial. Mental health support helps cope with chronic kidney disease. Depression and anxiety are common with kidney disease. Counseling helps address psychological effects. Support groups provide understanding from others. Family education helps loved ones understand disease. Open communication about disease progression helps relationships navigate changes. Work considerations are important. Many patients maintain employment despite kidney disease. Some might require reduced hours or different duties as disease progresses. Disability might become necessary if kidney failure develops. Financial planning becomes important as kidney disease progresses. Dialysis and transplantation create significant costs. Insurance and financial counseling help navigate expenses.

Frequently Asked Questions (FAQs)

Q1: Can IgA nephropathy be cured?

IgA nephropathy cannot be cured because the underlying autoimmune dysregulation is permanent. However, disease progression can be slowed through blood pressure control, ACE inhibitor/ARB therapy, and immunosuppressive treatment in some patients. With optimal management, many patients maintain adequate kidney function indefinitely. End-stage kidney disease requiring dialysis or transplantation develops in approximately 40 percent of patients over 20 years. Early diagnosis and aggressive treatment improve outcomes.

Q2: Why do some IgA nephropathy patients have no symptoms?

Many IgA nephropathy patients are asymptomatic because hematuria and proteinuria are present but not apparent to the patient. Microscopic hematuria is detected only by urinalysis. Microscopic proteinuria similarly requires testing to detect. Heavy hematuria or proteinuria might cause symptoms like foaming urine or tea-colored urine. However, early disease often causes no perceptible symptoms. Early detection through routine screening is crucial.

Q3: What triggers hematuria episodes in IgA nephropathy?

Upper respiratory infections commonly trigger gross hematuria episodes. The patient develops cold symptoms—sore throat, cough, or congestion. Days later, hematuria develops. The infection activates immune response that deposits additional IgA immune complexes in kidneys. Gastrointestinal infections might similarly trigger episodes. The relationship between infection and hematuria helps make IgA nephropathy diagnosis.

Q4: Is IgA nephropathy hereditary?

IgA nephropathy has genetic components—it runs in families. Specific genetic markers increase susceptibility. However, genetics alone does not cause disease. Environmental factors including infections are necessary. Familial IgA nephropathy exists but is uncommon. Most IgA nephropathy is sporadic. Family members of IgA nephropathy patients do not routinely need screening unless they have kidney symptoms.

Q5: Can someone with IgA nephropathy have a normal life expectancy?

Yes, many IgA nephropathy patients achieve normal or near-normal life expectancy. Patients with stable kidney function and slow disease progression might never develop kidney failure. Even patients developing end-stage kidney disease have good long-term survival with dialysis or transplantation. Early diagnosis and aggressive treatment improve long-term prognosis. Quality of life is usually good with appropriate management.

Key Takeaways

IgA nephropathy is a primary glomerulonephritis characterized by IgA immune complex deposition in kidney glomeruli. The disease is the most common primary glomerulonephritis worldwide. IgA immune complexes activate complement causing glomerular inflammation and damage. Hematuria and proteinuria are hallmark findings. Gross hematuria often triggered by infections is a common presentation. Progressive glomerular scarring leads to kidney failure if untreated. Kidney biopsy showing predominant IgA deposition confirms diagnosis. ACE inhibitors and ARBs reduce proteinuria and slow progression. Blood pressure control is fundamental in slowing disease. Immunosuppressive therapy helps some patients with aggressive disease. Approximately 40 percent of patients progress to end-stage kidney disease over 20 years. Early diagnosis and aggressive treatment improve outcomes. Dialysis or transplantation is necessary if kidney failure develops. With optimal management, many patients maintain adequate kidney function indefinitely. Life expectancy is usually normal with appropriate treatment.

References

1. World Health Organization (WHO). “IgA Nephropathy and Glomerulonephritis.” Retrieved from https://www.who.int/
2. American College of Rheumatology. “IgA Nephropathy: Clinical Guidelines.” Retrieved from https://www.rheumatology.org/
3. Mayo Clinic. “IgA Nephropathy: Causes and Treatment.” Retrieved from https://www.mayoclinic.org/
4. Cleveland Clinic. “IgA Nephropathy: Complete Information.” Retrieved from https://my.clevelandclinic.org/
5. National Kidney Foundation. “IgA Nephropathy Patient Resources.” Retrieved from https://www.kidney.org/
6. National Institute of Diabetes and Digestive and Kidney Diseases. “IgA Nephropathy.” Retrieved from https://www.niddk.nih.gov/

Related Articles on ObserverVoice.com

Explore more health and science topics on our platform:

• Understanding Autoimmune Diseases: When Your Immune System Attacks Itself
• The Kidneys: Function, Disease, and Renal Health
• Glomerulonephritis: Understanding Kidney Inflammation
• Chronic Kidney Disease: Understanding Progressive Renal Failure
• Blood Pressure: Understanding Hypertension and Kidney Disease
• Living with Chronic Illness: Adaptation and Support Strategies

Disclaimer

This article adapts publicly available information from WHO sources. This content is for informational and educational purposes only and does not constitute medical advice. [ObserverVoice.com] is a news and information platform — not a healthcare provider. If you suspect you have IgA nephropathy, experiencing hematuria or proteinuria, consult a qualified nephrologist for proper evaluation. Early diagnosis and treatment are crucial for slowing disease progression and preventing kidney failure. Always seek guidance from licensed healthcare specialists for diagnosis and treatment.

Observer Voice is the one stop site for National, International news, Sports, Editor’s Choice, Art/culture contents, Quotes and much more. We also cover historical contents. Historical contents includes World History, Indian History, and what happened today. The website also covers Entertainment across the India and World.

Follow Us on Twitter, Instagram, Facebook, & LinkedIn